These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. Novick D; Haro JM; Bertsch J; Haddad PM J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320 [TBL] [Abstract][Full Text] [Related]
6. Tardive dyskinesia in elderly patients: an update. Goldberg RJ J Am Med Dir Assoc; 2003; 4(2 Suppl):S32-42. PubMed ID: 12807568 [TBL] [Abstract][Full Text] [Related]
7. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management. Pierre JM Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025 [TBL] [Abstract][Full Text] [Related]
8. Effects of newer antipsychotics on extrapyramidal function. Tarsy D; Baldessarini RJ; Tarazi FI CNS Drugs; 2002; 16(1):23-45. PubMed ID: 11772117 [TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs]. Seigneurie AS; Sauvanaud F; Limosin F Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Tarsy D; Lungu C; Baldessarini RJ Handb Clin Neurol; 2011; 100():601-16. PubMed ID: 21496610 [TBL] [Abstract][Full Text] [Related]
11. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Masand PS; Gupta S Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433 [TBL] [Abstract][Full Text] [Related]
12. Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. Coplan J; Gugger JJ; Tasleem H J Affect Disord; 2013 Sep; 150(3):868-71. PubMed ID: 23726783 [TBL] [Abstract][Full Text] [Related]
13. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962 [TBL] [Abstract][Full Text] [Related]
15. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464 [TBL] [Abstract][Full Text] [Related]
16. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. Ryu S; Yoo JH; Kim JH; Choi JS; Baek JH; Ha K; Kwon JS; Hong KS J Clin Psychopharmacol; 2015 Feb; 35(1):13-21. PubMed ID: 25485636 [TBL] [Abstract][Full Text] [Related]
17. [Risk factors for tardive movement disorders in schizophrenia]. Tenback DE; Bakker PR; van Harten PN Tijdschr Psychiatr; 2015; 57(2):120-4. PubMed ID: 25669950 [TBL] [Abstract][Full Text] [Related]
18. Movement disorders associated with atypical antipsychotic drugs. Caroff SN; Mann SC; Campbell EC; Sullivan KA J Clin Psychiatry; 2002; 63 Suppl 4():12-9. PubMed ID: 11913670 [TBL] [Abstract][Full Text] [Related]
19. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. Lee PE; Sykora K; Gill SS; Mamdani M; Marras C; Anderson G; Shulman KI; Stukel T; Normand SL; Rochon PA J Am Geriatr Soc; 2005 Aug; 53(8):1374-9. PubMed ID: 16078964 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Tarsy D; Baldessarini RJ Mov Disord; 2006 May; 21(5):589-98. PubMed ID: 16532448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]